In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome
This study aims to determine the growth pattern and in vitro susceptibility of clinical isolates of Blastocystis hominis to different concentrations of metronidazole, furazolidone and ciprofloxacin. Stool specimens from 25 consecutive patients with irritable bowel syndrome presenting to the gastroen...
Gespeichert in:
| Veröffentlicht in: | British journal of biomedical science 2004-01, Vol.61 (2), p.75-77 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 2 |
| container_start_page | 75 |
| container_title | British journal of biomedical science |
| container_volume | 61 |
| creator | Yakoob, J. Jafri, W. Jafri, N. Islam, M. Asim Beg, M. |
| description | This study aims to determine the growth pattern and in vitro susceptibility of clinical isolates of Blastocystis hominis to different concentrations of metronidazole, furazolidone and ciprofloxacin. Stool specimens from 25 consecutive patients with irritable bowel syndrome presenting to the gastroenterology department of Aga Khan University Hospital between January and May 2003 are examined by microscopy and cultured for B. hominis. Drug susceptibility assays are performed for metronidazole, furazolidone, and ciprofloxacin using final concentrations of 0.01 mg/mL and 0.1 mg/mL. The effect of the drugs is assessed after B. hominis culture for 48 h. With furazolidone and metronidazole, 68 % (17/25) and 60 % (15/25) of B. hominis isolates, respectively, failed to grow at drug concentrations of both 0.01 mg/mL and 0.1 mg/mL. However, ciprofloxacin failed to suppress growth completely at both concentrations. B. hominis resistance to furazolidone, metronidazole and ciprofloxacin at 0.01 mg/mL was 32 % (8/25), 40 % (10/25) and 100 % (25/25), respectively. B. hominis isolates varied in their degree of susceptibility to the three drugs studied, being greater with furazolidone than with metronidazole, and complete resistance with ciprofloxacin. |
| doi_str_mv | 10.1080/09674845.2004.11732647 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_09674845_2004_11732647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66701970</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-84cbbff4a842d24459016b52bbe9ce17c81d36fa1bbd4b3a36a5d60d5145639c3</originalsourceid><addsrcrecordid>eNqF0TtvFDEQB3ALgcgR-AqRRUG3h19rr8sQ8YgUiQZqy0_FkXd92F5O--3x6S5CoqGa5jcz9vwBuMFoj9GEPiLJBZvYuCcIsT3GghLOxAuwI0ywAU2SvwS7ExpO6gq8qfUJISyJ4K_BFR7JiDiXO-DuF_g7tpJhXav1hxZNTLFtMAf4Kenast1qixU-5jkuvcaak27ewVDyDA-6Rb-0Co-xPcJYSmzaJA9NPvoE67a4rvxb8CroVP27S70GP798_nH3bXj4_vX-7vZhsFSSNkzMGhMC0xMjjjA2SoS5GYkxXlqPhZ2wozxobIxjhmrK9eg4ciNmI6fS0mvw4Tz3UPKv1dem5tg_lZJefF6r4lz0EwjU4ft_4FNey9LfpggRklAyTh3xM7Il11p8UIcSZ102hZE6haCeQ1CnENRzCL3x5jJ9NbN3f9suV-_g9gziEnKZ9TGX5FTTW8olFL3YWBX9z5I_3HeYUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227923258</pqid></control><display><type>article</type><title>In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Yakoob, J. ; Jafri, W. ; Jafri, N. ; Islam, M. ; Asim Beg, M.</creator><creatorcontrib>Yakoob, J. ; Jafri, W. ; Jafri, N. ; Islam, M. ; Asim Beg, M.</creatorcontrib><description>This study aims to determine the growth pattern and in vitro susceptibility of clinical isolates of Blastocystis hominis to different concentrations of metronidazole, furazolidone and ciprofloxacin. Stool specimens from 25 consecutive patients with irritable bowel syndrome presenting to the gastroenterology department of Aga Khan University Hospital between January and May 2003 are examined by microscopy and cultured for B. hominis. Drug susceptibility assays are performed for metronidazole, furazolidone, and ciprofloxacin using final concentrations of 0.01 mg/mL and 0.1 mg/mL. The effect of the drugs is assessed after B. hominis culture for 48 h. With furazolidone and metronidazole, 68 % (17/25) and 60 % (15/25) of B. hominis isolates, respectively, failed to grow at drug concentrations of both 0.01 mg/mL and 0.1 mg/mL. However, ciprofloxacin failed to suppress growth completely at both concentrations. B. hominis resistance to furazolidone, metronidazole and ciprofloxacin at 0.01 mg/mL was 32 % (8/25), 40 % (10/25) and 100 % (25/25), respectively. B. hominis isolates varied in their degree of susceptibility to the three drugs studied, being greater with furazolidone than with metronidazole, and complete resistance with ciprofloxacin.</description><identifier>ISSN: 0967-4845</identifier><identifier>EISSN: 2474-0896</identifier><identifier>DOI: 10.1080/09674845.2004.11732647</identifier><identifier>PMID: 15250669</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Animals ; Antiprotozoal Agents - pharmacology ; Blastocystis hominis ; Blastocystis hominis - drug effects ; Blastocystis hominis - growth & development ; Blastocystis Infections - drug therapy ; Ciprofloxacin ; Colonic Diseases, Functional - parasitology ; Diarrhea ; Drug Resistance ; Furazolidone ; Humans ; Intestinal Diseases, Parasitic - drug therapy ; Metronidazole ; Parasitic Sensitivity Tests</subject><ispartof>British journal of biomedical science, 2004-01, Vol.61 (2), p.75-77</ispartof><rights>Copyright 2004 Taylor and Francis Group LLC 2004</rights><rights>Copyright Step Publishing Ltd. 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-84cbbff4a842d24459016b52bbe9ce17c81d36fa1bbd4b3a36a5d60d5145639c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15250669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yakoob, J.</creatorcontrib><creatorcontrib>Jafri, W.</creatorcontrib><creatorcontrib>Jafri, N.</creatorcontrib><creatorcontrib>Islam, M.</creatorcontrib><creatorcontrib>Asim Beg, M.</creatorcontrib><title>In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome</title><title>British journal of biomedical science</title><addtitle>Br J Biomed Sci</addtitle><description>This study aims to determine the growth pattern and in vitro susceptibility of clinical isolates of Blastocystis hominis to different concentrations of metronidazole, furazolidone and ciprofloxacin. Stool specimens from 25 consecutive patients with irritable bowel syndrome presenting to the gastroenterology department of Aga Khan University Hospital between January and May 2003 are examined by microscopy and cultured for B. hominis. Drug susceptibility assays are performed for metronidazole, furazolidone, and ciprofloxacin using final concentrations of 0.01 mg/mL and 0.1 mg/mL. The effect of the drugs is assessed after B. hominis culture for 48 h. With furazolidone and metronidazole, 68 % (17/25) and 60 % (15/25) of B. hominis isolates, respectively, failed to grow at drug concentrations of both 0.01 mg/mL and 0.1 mg/mL. However, ciprofloxacin failed to suppress growth completely at both concentrations. B. hominis resistance to furazolidone, metronidazole and ciprofloxacin at 0.01 mg/mL was 32 % (8/25), 40 % (10/25) and 100 % (25/25), respectively. B. hominis isolates varied in their degree of susceptibility to the three drugs studied, being greater with furazolidone than with metronidazole, and complete resistance with ciprofloxacin.</description><subject>Animals</subject><subject>Antiprotozoal Agents - pharmacology</subject><subject>Blastocystis hominis</subject><subject>Blastocystis hominis - drug effects</subject><subject>Blastocystis hominis - growth & development</subject><subject>Blastocystis Infections - drug therapy</subject><subject>Ciprofloxacin</subject><subject>Colonic Diseases, Functional - parasitology</subject><subject>Diarrhea</subject><subject>Drug Resistance</subject><subject>Furazolidone</subject><subject>Humans</subject><subject>Intestinal Diseases, Parasitic - drug therapy</subject><subject>Metronidazole</subject><subject>Parasitic Sensitivity Tests</subject><issn>0967-4845</issn><issn>2474-0896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqF0TtvFDEQB3ALgcgR-AqRRUG3h19rr8sQ8YgUiQZqy0_FkXd92F5O--3x6S5CoqGa5jcz9vwBuMFoj9GEPiLJBZvYuCcIsT3GghLOxAuwI0ywAU2SvwS7ExpO6gq8qfUJISyJ4K_BFR7JiDiXO-DuF_g7tpJhXav1hxZNTLFtMAf4Kenast1qixU-5jkuvcaak27ewVDyDA-6Rb-0Co-xPcJYSmzaJA9NPvoE67a4rvxb8CroVP27S70GP798_nH3bXj4_vX-7vZhsFSSNkzMGhMC0xMjjjA2SoS5GYkxXlqPhZ2wozxobIxjhmrK9eg4ciNmI6fS0mvw4Tz3UPKv1dem5tg_lZJefF6r4lz0EwjU4ft_4FNey9LfpggRklAyTh3xM7Il11p8UIcSZ102hZE6haCeQ1CnENRzCL3x5jJ9NbN3f9suV-_g9gziEnKZ9TGX5FTTW8olFL3YWBX9z5I_3HeYUA</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>Yakoob, J.</creator><creator>Jafri, W.</creator><creator>Jafri, N.</creator><creator>Islam, M.</creator><creator>Asim Beg, M.</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20040101</creationdate><title>In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome</title><author>Yakoob, J. ; Jafri, W. ; Jafri, N. ; Islam, M. ; Asim Beg, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-84cbbff4a842d24459016b52bbe9ce17c81d36fa1bbd4b3a36a5d60d5145639c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antiprotozoal Agents - pharmacology</topic><topic>Blastocystis hominis</topic><topic>Blastocystis hominis - drug effects</topic><topic>Blastocystis hominis - growth & development</topic><topic>Blastocystis Infections - drug therapy</topic><topic>Ciprofloxacin</topic><topic>Colonic Diseases, Functional - parasitology</topic><topic>Diarrhea</topic><topic>Drug Resistance</topic><topic>Furazolidone</topic><topic>Humans</topic><topic>Intestinal Diseases, Parasitic - drug therapy</topic><topic>Metronidazole</topic><topic>Parasitic Sensitivity Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yakoob, J.</creatorcontrib><creatorcontrib>Jafri, W.</creatorcontrib><creatorcontrib>Jafri, N.</creatorcontrib><creatorcontrib>Islam, M.</creatorcontrib><creatorcontrib>Asim Beg, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of biomedical science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yakoob, J.</au><au>Jafri, W.</au><au>Jafri, N.</au><au>Islam, M.</au><au>Asim Beg, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome</atitle><jtitle>British journal of biomedical science</jtitle><addtitle>Br J Biomed Sci</addtitle><date>2004-01-01</date><risdate>2004</risdate><volume>61</volume><issue>2</issue><spage>75</spage><epage>77</epage><pages>75-77</pages><issn>0967-4845</issn><eissn>2474-0896</eissn><abstract>This study aims to determine the growth pattern and in vitro susceptibility of clinical isolates of Blastocystis hominis to different concentrations of metronidazole, furazolidone and ciprofloxacin. Stool specimens from 25 consecutive patients with irritable bowel syndrome presenting to the gastroenterology department of Aga Khan University Hospital between January and May 2003 are examined by microscopy and cultured for B. hominis. Drug susceptibility assays are performed for metronidazole, furazolidone, and ciprofloxacin using final concentrations of 0.01 mg/mL and 0.1 mg/mL. The effect of the drugs is assessed after B. hominis culture for 48 h. With furazolidone and metronidazole, 68 % (17/25) and 60 % (15/25) of B. hominis isolates, respectively, failed to grow at drug concentrations of both 0.01 mg/mL and 0.1 mg/mL. However, ciprofloxacin failed to suppress growth completely at both concentrations. B. hominis resistance to furazolidone, metronidazole and ciprofloxacin at 0.01 mg/mL was 32 % (8/25), 40 % (10/25) and 100 % (25/25), respectively. B. hominis isolates varied in their degree of susceptibility to the three drugs studied, being greater with furazolidone than with metronidazole, and complete resistance with ciprofloxacin.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>15250669</pmid><doi>10.1080/09674845.2004.11732647</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0967-4845 |
| ispartof | British journal of biomedical science, 2004-01, Vol.61 (2), p.75-77 |
| issn | 0967-4845 2474-0896 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_09674845_2004_11732647 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Animals Antiprotozoal Agents - pharmacology Blastocystis hominis Blastocystis hominis - drug effects Blastocystis hominis - growth & development Blastocystis Infections - drug therapy Ciprofloxacin Colonic Diseases, Functional - parasitology Diarrhea Drug Resistance Furazolidone Humans Intestinal Diseases, Parasitic - drug therapy Metronidazole Parasitic Sensitivity Tests |
| title | In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A34%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20susceptibility%20of%20Blastocystis%20hominis%20isolated%20from%20patients%20with%20irritable%20bowel%20syndrome&rft.jtitle=British%20journal%20of%20biomedical%20science&rft.au=Yakoob,%20J.&rft.date=2004-01-01&rft.volume=61&rft.issue=2&rft.spage=75&rft.epage=77&rft.pages=75-77&rft.issn=0967-4845&rft.eissn=2474-0896&rft_id=info:doi/10.1080/09674845.2004.11732647&rft_dat=%3Cproquest_cross%3E66701970%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227923258&rft_id=info:pmid/15250669&rfr_iscdi=true |